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1. Introduction 
The incidence of heart failure (HF) after acute myocardial infarction (AMI) is around 10-40% 
during the hospital stay depending on its definition (Weir & McMurray, 2006; Cleland & 
Torabi, 2005). Also, another 10-20% of patients will develop heart failure symptoms during 
the next few months and years (Torabi et al., 2008). The mortality of patients with heart 
failure symptoms after AMI is very high and it reaches up to 50% in 5 years (Weir & 
McMurray, 2006; Fox et al, 2006). The left ventricle dilatation occurs in even 30% in patients 
reperfused successfully with primary angioplasty during six months follow-up (Bolognese 
el al, 2002) and the occurrence of dilatation is more pronounced in patients with lower 
baseline left ventricle ejection fraction (LVEF). The incidence of HF after AMI has increased, 
and mortality decreased over time with the better reperfusion therapy (Velagaleti et al, 
2008). According to these facts, it is extremely important to develop therapeutic modalities 
in order to prevent the remodeling of myocardium after infarction. The adult stem cell 
therapy is a relatively new and promising method of an infarcted heart healing and HF 
prevention.   
In the last two decades three important discoveries regarding different regenerative steps of 
damaged myocardium promoted the completely new era in the treatment of ischemic heart 
disease. First of all, several adult multipotent and pluripotent stem cells from different 
tissues may trans-differentiate in certain circumstances to cardiomyocytes or other needed 
cells, such as endothelial cells (Körbling M & Estrov Z, 2003; Müller et al, 2005). However, in 
vivo, this mechanism of heart regeneration seems to be negligible (Wagers et al, 2002; Murry 
et al, 2004), at least for the acute injury. The second is the fact that a significant number of 
cardiac cells are in the proliferative state in the areas of myocardium adjunction to infarction 
(Beltrami et al, 2001). The first source of these regenerative cells is very probably resident 
cardiac stem cells which are in the quiescent state out of injury, but in the time of infarction 
they proliferate and differentiate to cardiomyocytes, smooth muscle cells and endothelial 
cells (Bollini et al, 2011). And the third important discovery is that in the time of infarction, 
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myocardial ischemia initiates the eruption of cytokines, growth-factors and chemokines 
from the injured myocardium which promote mobilization of stem cells from other niches 
and their homing into the damaged myocardium (Frangogiannis, 2008). The most likely 
function of these cells in the ischemic myocardium are various paracrine effects which 
enable survival of severely damaged cardiomyocytes, promote differentiation and the 
proliferation of cardiac stem cells and participate in the creation of new blood vessels which 
all halted myocardial remodeling and the development of heart failure (Mirotsou et al, 
2011). 
The knowledge of these processes is very important because the regenerative therapy  
depends on artificial augmentation of some steps in order to make regenerative process 
more efficient. The most important steps are shown in figure one. Ischemic injury induces 
the hypoxia-inducible factor-alpha which in turns stimulates the expression of several 
growth factors and chemokines in the infracted heart (Dong et al, 2010). Those cytokines, 
especially stromal derived factor-1, interleukin-8 and vascular-endothelial growth factor 
promote mobilization of local and remote stem cells and enable engraftment of them into 
the damaged tissue (Figure 1).  
 
 
Fig. 1. Mobilization of stem cells by the cytokine and chemokine storm after myocardial 
infarction and potential paracrine effect of stem cells in the infracted heart and beneficial 
effect on cardiomyocytes survival, promotion of angiogenesis and inhibition of remodeling 
HIF-α – hypoxia inducible factor-alpha, IGF-1 – insulin-like growth factor – 1, HGF – 
hepatocyte growth factor, SDF-1alpha – stromal cell-derived factor 1 alpha, VEGF - vascular 
endothelial growth factor, G-CSF- granulocyte colony-stimulating factor, IL8 - interleukin 8, 
PTH - parathyroid hormone, MCP-1 – monocyte chemoattractant protein-1, KDR – receptor 
for VGEF, CXC4R – receptor for SDF-1, CXCR1/2 receptors for other chemokines, SFRP2 – 
signaling protein important for cardiomyocyte survival. 
Chemokine receptors (CXC-R1 and CXC4R), growth receptors (VGFR) and several selectins 
and integrins on stem cells are important for the successful homing of these cells in the 
ischemic myocardium (Chavakis et al, 2008). Expression of matrix metalloproteinases such 
as MMP-2, 9 and cathepsin by stem cells represent the final step of their transmigration into 
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the damaged tissue (Cheng et al, 2007; Huang et al, 2009). Several growth factors up-
regulated by ischemia (insulin growth factor-1, hepatocyte growth factor, fibroblast growth 
factor) enable the survival of these cells in the hostile environment (Frangogiannis, 2008).  
Paracrine effects of stem cells promote local cardiomyocytes survival, neovascularization, 
attenuate the remodeling and improve cardiac function. Among several niches of stem cell 
residency, myocardium itself, bone marrow and adipose tissue are probably the most 
important reservoir of this regenerative capacity. The advance age, large necrosis and 
enhanced inflammatory reaction decrease the stem cell mobilization after infarction (Turan 
et al, 2007).   
2. Important clinical trials on stem cell therapy in acute myocardial infarction 
Several clinical studies investigated the usage of bone marrow derived cells for the 
treatment of AMI. The most of them used autologous bone marrow derived mononuclear 
(MNC) cell suspensions with intracoronary delivery through the inflated balloon placed on 
the spot of previous stent placement (Abdel-Latif et al, 2007; Tongers et al, 2011).  The 
pioneering study of Strauer (Strauer et al, 2002), on 20 AMI was not randomized, but had 
the well matched control group that showed improved left ventricular systolic function and 
perfusion in the short and long-term follow-up. After that study several randomized studies 
were published with the conflicting results (Table 1). Transplantation of Progenitor Cells  
and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE study) 
compared bone marrow derived MNC and circulating progenitor cells (CPS) given 
intracoronary but without the control group (Schachinger et al, 2004). Both systolic function 
and viability improved in the similar way after 4 months follow-up. In the study of Chen et 
al (Chen et al, 2004) intracoronary injections of mesenchymal stem cells were used for the 
first time in humans, and with the sophisticated methodology they demonstrated that this 
method was safe, feasible and that it significantly improved global and regional left 
ventricle function. Interestingly, there was no trial with the use of MSC intracoronary 
after Chen’s study. In  BOO transfer  to enhance ST-elevation infarct regeneration 
(BOOST)  trial (Schafer et al, 2006) with magnetic resonance imaging (MRI) of left 
ventricle ejection fraction (LVEF) and volumes for follow-up, single dose of intracoronary 
bone marrow cell provided the accelerate improvement of systolic function (after 6 
months) with the late catch-up of the control group (after 18 months). In the study of 
Janssens et al, intracoronary transfer of bone marrow MNC was done 24 hours after 
primary percutaneous coronary intervention (PCI) and did improve only regional, but not 
the global left ventricle systolic function after 4 months by the MRI imaging (Jansenss et 
al, 2006). Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute 
Myocardial Infarction (REPAIR-AMI) trial (Schachinger et al, 2006a, 2006b) is the largest 
randomized trial that examined the intracoronary transfer of bone marrow derived MNC 
and it brought interesting results. For the first time one of the inclusion criteria for the 
participation in the study was the baseline LVEF measured at the time of primary PCI. 
The significant improvement of LVEF was detected in the cell therapy group compared to 
controls and it was more pronounced in patients with the baseline LVEF less than median 
(48.9%) and in those in whom cell transfer was performed later than the 4-post infarction 
day. The most important result of this trial was that the combined end point death and 
recurrence of myocardial infarction and rehospitalization for heart failure, was 
significantly reduced in the BMC group after two years follow-up (Assmus et al, 2010).  
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Method of 
SC 
delivery 
Number of patients 
and type of cells 
N 
Timing 
(d) 
Bone marrow volume, 
method of cell 
preparation and the 
number of cells 
Criteria for 
patient 
selection 
The basic result 4-6 
months after 
STEMI 
I.C. short 
FU 
     
Strauer et 
al. 
10 BMMNC/10 C 5-9 40 ml, Ficoll, 2.8±2.2x107 
MNC 
First 
STEMI, 
pPCI 
ECHO, LVA, PET - 
EF, volumes, 
perfusion ↑ 
TOPCARE 29 BM-MNC/30 CPC 4-6 50 ml, Ficoll 
5±3x106 
CD34+/16±12x106CPC
First 
STEMI, 
pPCI 
ECHO, RVA, MRI – 
EF, volumes, 
perfusion↑ 
Chen 34 BM-MSC/35 C 8/16 
Harv/
deli 
60 ml, MSC culture 
8-10x109 MSC 
First 
STEMI, 
pPCI 
ECHO, PET – EF, 
volumes, 
perfusion↑ 
BOOST 30 BMC/30 C 5-7 120 ml, gelatin-
polysuccinate, 
9.5±6.3x106 CD34+ 
First 
STEMI, 
pPCI 
MRI - EF↑ at six but 
not at 18 months 
Jansens 
 
33 BMMNC/34 C 
 
1 130 ml, Ficoll, 
2.8±1.7x106 CD34+ 
First 
STEMI, 
pPCI 
ECHO, MRI - EFņ, 
regional function↑ 
REPEAR-
AMI 
101 BMMNC/103 C 3-6 
 
50 ml, Ficoll, 3.6±3.6x106 
CD34+ 
 
First 
STEMI, 
pPCI, 
EF≤45% 
LVA - EF↑ 
Comp hard end 
pointŅ 
ASTAMI 
 
50 BMMNC/47 C 
 
4-7 
 
50 ml, Lymphoprep, 
0.7x106 CD34+ 
First 
STEMI, 
pPCI on 
LAD 
ECHO-EF, SPECT, 
MRI – EF and 
volumesņ 
Meluzin 
 
22 HD-BMMNC/22 
LD-BMMNC/22 C 
5-9 
 
NS, Histopaque-buffy-
coat, HD-108 MNC, LD-
107 MNC 
First STEMI
pPCI 
ECHO, gSPECT - 
↑EF, Ņvolumes, HD 
better 
REGENT 80 NS-BMMNC/80 
CD34+/CXC4R+BM
Cells/40 C* 
3-12 100-120 ml-selected cell 
group and 50-70 ml-
unselected group, 
Ficoll/selection 1.8x108 
cells/1.9x106 
CD34+CXCR4+ 
First 
STEMI, 
LAD-IRA, 
EF≤40% 
 
MRI – EF and 
volumesņ, EF and 
volumes↑ in pts 
with EF<37% 
(median) 
 
FINCELL 
 
40 BMMNC/40 C 
 
2-6 (after
PES 
stent) 
80 ml, Ficoll, 2.6±1.6x106 
CD34+ 
 
First 
STEMI, 
Fibrinolysis
ECHO, LVA - EF↑ 
IVUS - MLAņ 
HEBE 
 
69 BMMNC/66 
PBMNC/ 
65 C 
3-8 
 
60 ml BM, 150-200 ml 
PB, Lymphoprep, 
4.0(2.1-6.5)x106 
CD34+/0.3(0.2-0.4)x106 
CD34+ 
First 
STEMI, 
pPCI 
 
MRI - EF, IS and 
regional functionņ 
 
I.C.long 
FU 
     
BALANCE 62 BMMNC/62 C 
 
5-10 
 
80-120 ml, Ficoll, 
6.1±3.9x107 BMC 
First 
STEMI, 
pPCI 
LVA, dECHO - EF↑, 
arrhythmiasŅ, 
mortalityŅ 
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Method of 
SC 
delivery 
Number of patients 
and type of cells 
N 
Timing 
(d) 
Bone marrow volume, 
method of cell 
preparation and the 
number of cells 
Criteria for 
patient 
selection 
The basic result 4-6 
months after 
STEMI 
CAO 
 
41 BMMNC/46 C 
 
7 
 
40 ml, 
Lymphoprep,5x108MNC 
(1.8±0.6%CD34+) 
First 
STEMI, 
pPCI on 
LAD 
gSPECT - EF↑, 
viabilityņ 
 
BOOST 5y 
 
27 BMMNC/26 C 
 
5-7 
 
120 ml, gelatin-
polysuccinae, 
9.5±6.3x106 CD34+ 
First 
STEMI, 
pPCI 
MRI – EF and 
volumesņ 
Repeated  
I.C. 
     
Yao 12 S-i.c.BMMNC 
transfer/15 R-
i.c.BMMNC - 3 
months/12 C 
7 d and 
90 d 
90 ml, Ficoll, 1.9-2.1x108 
BMC in both groups 
and in repeat infusion 
First 
STEMI, EF 
20-39% 
MRI EF↑ highest in 
repeat cell group 
I.V.      
Hare 39 alloMSC (0.5 vs 
1.6 vs 5.0x106/kg) 
/21 C 
1-10 Single unrelated donor 
no HLA matched 
First 
STEMI, 
pPCI 
ECHO-EF antMI↑, 
MRI-EF↑ 
Endocardial      
MYSTAR 
 
30 EG/30 LG 
 
3-6 w vs.
3-4 m 
300 ml, COBE-vol. depl.
EG: 3.6x106 CD34+i.m. 
+23.2.4x106CD34+i.c. 
LG: 3.0.3x106 CD34+i.m. 
+22.5x106CD34+ i.c. 
First 
STEMI, 
pPCI, 
30-45%EF 
 
SPECT-EF↑ in both 
groups, no 
difference between 
groups 
 
SC- stem cells, I.C.- intracoronary, I.V. intravenously, FU- follow-up, BMC-Bone marrow cells, BM-
MNC – Bone marrow mononuclear cells, CPC-circulating progenitor cells, Bone marrow mesenchimal 
stem cells, HD-MMNC – higher dose of BMMNC-108, LD-BMMNC-lower dose BMMNC-107, PBMNC-
peripheral blood mononuclear cells, C-controls, PES- paclitaxel eluting stent, STEMI- ST elevation 
myocardial infarction, pPCI- primary percutaneous coronary intervention, antMI – anterior myocardial 
infarction,  LAD- left anterior descending, IA- infarction related artery,  EG – early group, LG – late 
group, dECHO- dobutamine echocardiography, gSPECT- gated single-photon emission computed 
tomography, PET- positron emission tomography, MRI- magnetic resonance imaging, LVA- left 
ventricle angiography, EMM- electro-mechanical-mapping,  IVUS- intravascular ultrasound, MLA- 
minimal lumen area, EF- ejection fraction. 
Table 1. Important clinical trials of stem cell therapy in acute myocardial infarction. 
Autologous Stem-Cell Transplantation in Acute Myocardial infarction trial (ASTAMI) also 
used some inclusion criteria for attention to recruit more severe seek patients (Lunde et al, 
2006). The inclusion criterion in this study, among the presence of the first STEMI, was the 
finding on coronarography with the culprit lesion on the proximal part of the left anterior 
descending artery (LAD). However, more than 25% of patients in both groups (cell group 
and control) had the TIMI-2/3 flow before the primary percutaneous coronary intervention 
(PCI) and the baseline mean LVEF measured by three methods (echocardiography, single 
photon computed tomography-SPECT and MRI) was greater than 40%, which means that 
this group did not represent the anterior STEMI realistically. This study showed no effects of 
cell therapy on global LVEF. The other probably important pitfall of this study was the late 
baseline MRI imaging, after 3 weeks of stem cell infusion which could have missed some 
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early action of stem cells. Different protocols of bone marrow mononuclear cell preparation 
(for instance - Lymphoprep gradient media in ASTAMI and Ficoll in REPAIR-AMI) among 
the studies might be the reason for these discrepant results, but there are certain 
controversies about that issue (Seeger et al, 2007; Yeo et al, 2009).  Meluzin et al, addressed 
the question of “cell dosage” for the intracoronary infusion after STEMI in their study 
(Meluzin et al, 2006). Although some other studies did not found such relationship 
(TOPCARE, REGENT), improvement of regional LV function was “cell-dose” dependant in 
this study. Regeneration by Intracoronary Infusion of Selected Population of Stem Cell in 
Acute Myocardial Infarction (REGENT) trial (Tendera et al, 2009) is important for two 
reasons. The first is the patients’ selection, with the enrollment of patients with more severe 
LVEF impairment (LVEF≤40%) and the second is the immunomagnetic selection of bone 
marrow MNC for CD34+/CXC4R+ cells which represents the “selection” arm in this study. 
Unfortunately MRI follow-up was paired in only 59% of patients. Again, patients with 
baseline LVEF less than median had the significant improvement of LVEF after 6 months in 
both cell groups (selected and non-selected). However, the median baseline LVEF value in 
this study was 37%, meaning that a half of patients have had the baseline LVEF between 37-
40%, probably indicating the recruitment bias in this study. The FIN study of autologous 
bone marrow-derived stem CELLs in acute myocardial infarction (FINCELL) for the first 
time used intracoronary stem cell therapy a few days after successful thrombolysis (Huikuri 
et al, 2008). The intracoronary injections of bone marrow MNC were given immediately 
after percutaneous coronary intervention which was performed on the already opened 
infarct related artery. Intracoronary injections of stem cells in these patients were feasible 
and associated with the improvement of LVEF after 6-months. Meticulous assessment of 
arrhythmogenic potential of stem cells was done in this study using three non-invasive 
methods (Holter monitoring, microvolt T wave alternans and Signal-averaged 
electrocardiogram) having proved that intracoronary bone marrow cell therapy did not 
seriously aggravate arrhythmias. Intravascular ultrasound imaging performed in this study 
confirmed that cell therapy did not cause restenosis. The HEBE trial (Hirsch et al, 2010) 
investigated the influence of bone marrow compared to peripheral blood derived MNC 
intracoronary and controls to global and regional LV function measured by MRI. This 
relatively large trial resulted in neutral influence of cell therapy on LV performance after 6 
months. The relatively short ischemia time in this trial may explain the equal and significant 
recovery of LVEF in all three arms of this trial.  Besides, the baseline LVEF was above the 
40% (median=43.4%) pointing that the majority of patients in this study had good prognosis 
and no additional benefit of stem cell therapy should be expected. Indeed, there was a trend 
toward better results of stem cell therapy according to percent of the regional segment 
improvement in patients with baseline LVEF bellow the median value. The French study 
(Roncalli et al, 2010) was concentrated to the scintigraphy analysis of viability after 
intracoronary infusion of bone marrow derived MNC. Patients with more severe infarction 
(LVEF≤45%) were enrolled in this study. Bone marrow cells slightly improved viability in 
cell therapy group. This study also emphasized the negative impact of smoking on the 
improvement of viability during time.  
Only three trials published their long-term results of intracoronary bone marrow derived 
cell therapy in the acute phase of STEMI.  Strauer’s group, in their non-randomized, but well 
controlled study had showed that the benefit on intracoronary bone marrow derived MNC 
infusion after infarction for the myocardial performance sustained after 5 years and that 
even decreased the abnormal heart rate variability, late potentials and ectopic beats (Yousef 
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et al, 2009). And the most important, mortality of BMC-treated patients was significantly 
reduced in comparison with the control group. The long-term study of Chinese group (Cao 
et al, 2009), also indicated the persistent improvement of LVEF (over 4 years) in AMI 
patients treated with intracoronary bone marrow MNC compared to controls, but 
interestingly without significant improvement on viability. In BOOST trial (Meyer et al, 
2009) patients with more transmural extension of infarction appeared to benefit from BMC 
transfer throughout the five years.   
Most likely, single intracoronary cell infusion cannot bring enough stem cells into the 
infarction area for the sustained beneficial effect on the myocardial function. There is  
probably the saturation level of stem cell delivery in such short period of time which 
precludes their significant influence on myocardial regeneration in patients with very large 
myocardial necrosis. Yao’s group, in their relatively small study suggested that repeated 
intracoronary stem cell therapy, after 3-7 days from STEMI and again after 3 months may 
have an additional advantage in comparison to single early stem cell treatment (Yao et al, 
2009).  
The extraordinary trial comes from the Hare’s group, who for the first time used 
intravenous allogeneic mesenchymal stem cells infusion from the healthy unrelated bone 
marrow donor in patients with STEMI (Hare et al, 2009). Mesenchymal stem cells lack major 
histocompatibility complex and costimulatory cell-surface antigens which enable their 
allogeneic transfer and secret various anti-inflammatory cytokines promoting healing. They 
are also rich in the homing properties which allow intravenous application. This study 
performed detailed safety assessment including pulmonary function and computed 
tomography of chest abdomen and pelvis in the follow-up. Mesencymal stem cell therapy 
demonstrated reduced ventricular tachycardia, better pulmonary function and increase of 
LVEF in patients with anterior infarction compared to controls. 
Two trials examine the safety, feasibility and efficacy of trans-endocardial route of bone 
marrow derived MNC delivery using electromechanical mapping as the guidance (NOGA 
system) after AMI. MYSTAR trial (Gyöngyösi et al, 2009) compared early (3 weeks after 
AMI) and late (3 months after AMI) combined trans-endocardial and intracoronary bone 
marrow derived MNC. In both arms cell therapy achieved small but significant 
improvement of LVEF measured by g-SPECT. This study used a large number of CD34+ 
cells, and the majority of cells were given intracoronary. Unfortunately this study had no 
arms with intracoronary and trans-endocardial route of delivery separately and we do not 
know if the combined route of stem cell delivery has any synergistic effect. Krause et al, 
published their small, uncontrolled study with early trans-endocardial delivery of bone 
marrow MNC in AMI, and they proved its safety with the significant improvement of LVEF 
after six months (Krause et al, 2009).  
Several studies (Table 2) investigated the usage of granulocyte growth factor (G-CSF) for 
induction of longer and increased mobilization of stem cells during the first days of AMI 
(Valgimigli et al, 2008). The application of G-CSF for several days achieved the 10-30 times, 
increased of CD34+ cells number in peripheral blood (Ince et al, 2005; Valgimigli et al, 2005; 
Zohlnhöfer et al, 2006; Engelman et al, 2006; Ripa et al, 2006; Takano et al, 2007; Leone et al, 
2007). When we analyzed the results of these studies it seemed that very early start of G-CSF 
after STEMI (during the first day) and its application in patients with lower LVEF (lower 
than 40%) had a positive effect on systolic function (Ince et al, 2005; Takano et al, 2007; 
Leone et al, 2007). However, G-CSF had some potential prothrombotic and pro-
inflammatory effects (Le Blanc et al, 1999; Falanga et al, 1999) which could be deleterious for 
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patients with AMI, but it was not seen in the current published trials. Parathyroid hormone 
or its analogs may be an alternative drug for stem cell mobilization in this setting (Huber et 
al, 2010). 
 
Study 
The number of 
patients 
Time 
GCSF 
Duration of G-CSF 
therapy and dosage 
Patient 
selection 
Results of the 
study 
FIRSTLINE-
AMI 
25GCSF/10 C 
 
1.5 h-
pPCI 
6d, 10 μg/kg/d s.c. 1st-AIM, 
pPCI 
ECHO-EF I 
WMSI↑, PET ↑ 
STEMMI 
 
39 GCSF/39C 
 
2 d 
 
6d, 10 μg/kg/d s.c. 1st AIM, 
pPCI 
MRI wall thick, 
EFņ, 
G-CSF-STEMI 
 
23 GCSF/21C 
2 d 
 
5 d, 10 μg/kg/d sc 
 
1st AIM, 
pPCI 
MRI-EF, vol. 
and reg. 
functionņ, 
perfusion↑ 
REVIVAL-2 
 
58 GCSF/56C 
5 d 
 
5d, 10 μg/kg/d s.c. 
1st AIM- 
lysis, PCI 
5d 
SPECT IS ņ, 
MRI-EFņ 
REGENERA 
 
14 GCSF/27C 
 
≥5 d 
 
5d,10 μg/kg/d s.c. 
 
1stant 
AIM 
EF<50% 
ECHO-EF, vol. 
and WMSI↑ 
TAKANO 22 GCSF/18C 1 d 5d,2.5 μg/kg/d s.c. 
1st ant 
AIM 
pPCI 
gSPECT-EF, vol. 
IS↑ 
Table 2. Important clinical trials used mobilization of stem cells to treat acute myocardial 
infarction.GCSF- Granulocyte colony-stimulating factor, AIM - ST elevation myocardial 
infarction, pPCI- primary percutaneous coronary intervention, dECHO- dobutamine 
echocardiography, EF- ejection fraction, WMSI- wall motion score index, EDV- end-diastolic 
volume, gSPECT- gated single-photon emission computed tomography, PET- positron 
emission tomography, MRI- magnetic resonance imaging 
3. Important clinical trials on stem cell therapy in chronic myocardial 
infarction 
The chronic myocardial infarction (CMI) represents a completely different environment 
for the stem cell therapy. The precise definition of chronic is not established, but it seems 
that it would be accepted that the chronic MI may be old at least 1-2 months after the 
necrotic event. Highly dynamic inflammatory reaction with cellular and cytokine storm is 
finished and slow fibrotic process replaces it (Frangogiannis, 2008). The abundance of 
chemokines, growth factors, adhesion molecules and other biologically active substances 
in the acute inflammatory phase of infarction not longer exist. Some parts of myocardium 
adjacent to infarction core due to long time of ischemia and because of partly damaged 
structure after the index event are alive but not capable for fully function. Those areas 
need revitalization with stem cells, but the question is whether the same cells are needed 
for the chronic IM as for the acute MI, and whether the same route of delivery would be 
equally efficient?  Very interested human pilot study of tracking the labeled circulating 
progenitor cells (CPC) with indium oxine (111 In-oxine) after intracoronary injections in 
patients with acute (<15 days), intermediate phase (15 days-1 year) and a late chronic 
stage of MI (>1 year), demonstrated that amount of progenitor cells retained in the 
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myocardium decreased progressively over the time (Schächinger et al, 2008) alludes the 
answer on the second question. Human trials comparing bone marrow derived MNC and 
peripheral blood progenitor cells (PBPC) exist at least for AMI patients with inconclusive and 
contradictory results on their regenerative capacity (Schächinger et al, 2004; Hirsch et al, 2010). 
However, those cells are very similar but the only difference is that bone marrow MNC cells 
have more primitive cell subpopulation then PBPC which are more commitment to 
endothelial lineage. The comparison of mesenchymal stem cells and hematopoietic CD34+ 
cells in animal model of myocardial infarction showed that mesenchymal stem cells were more 
potent for the healing of the heart (Arminan et al, 2010).  
 
Method 
of SC 
delivery 
Study 
Number of 
patients In groups 
Timing 
of SC 
therapy 
after  MI 
Bone marrow 
volume, the 
number of cells 
Selection 
of the 
patients 
The main results 
of the study 
I.C.  
TOPCA
RE-CHD 
28 BMMNC/24 
CPC/23 C 
>3 m 
50 ml BM, 270 m 
PB, Ficoll, 
2.0±1x106MNC/ 
22±11x106CPC 
Patent IRA 
 
LVA, MRI, PET - 
EF↑, regional 
function↑ - 
BMMNC 
STAR 
191 BMMNC/200 
C 
8.5±3.2 y 
80-120 ml, Ficoll, 
6.6x107BMC 
Patent IRA 
by PCI, 
EF≤35% 
LVA, EF and 
regional 
function↑, 
exercise 
capacity↑, 
MortalityŅ 
MAGIC-
DES 
 
25 BMMNC-
AMI/25 AMI-C/ 
16 BMMNC-
CMI/16 CMI-C 
≤14 d, 
2±3 d- 
AIM/>1
4 d-CMI 
≈2 y 
GCSF s.c.10μg/kg 
3d, 4 d COBE-BCT, 
1.4x109 Leu, CD34- 
9.2±10.4% 
Patent IRA 
MRI-EF ↑ in AMI 
CPC group, in 
CMI ņ 
I.C. vs. 
I.M. 
     
Ang et al 
 
21 BMMNC IC/ 21 
BMMNC IM/ 20 C 
>6 w 
80 ml, 
Lymphoprep, 
1.4x105 CD34+ 
I.M./2.4x105 
CD34+ I.C. 
Graftable 
infarct 
area 
d-ECHO, MRI – 
EF and regional 
functionņ in all 
groups 
Epicardial  
Patel 
 
10 BMMNC/ 10 c 
 
NS 
550 ml, Ficoll, 
immuno-magnetic 
sel. 22x106CD34+ 
Graftable 
infract 
area, 
EF≤35% 
ECHO, gSPECT 
– EF↑ 
Mocini 
 
18 BMMNC/18 C 
Recent 
MI >4 w 
and < 6 
m 
50 ml, seeded with 
HES, 
centrifugation, 
3.7x109CD34+  
after CABG during 
arrest 
Graftable 
infract 
area, 
LVEF≥35% 
 
MRI – EF↑ and 
WMSIŅ 
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Method 
of SC 
delivery 
Study 
Number of 
patients In groups 
Timing 
of SC 
therapy 
after  MI 
Bone marrow 
volume, the 
number of cells 
Selection 
of the 
patients 
The main results 
of the study 
Hendrik
x 
10 BMMNC/10 C 
 
217±162 
d 
 
40 ml, 
Lymphoprep, 
60.2x106 BMC, 
CD34% 1.4±1.0 
Graftable 
infract 
area 
MRI - EFņ,, 
SPECT – 
viability ņ 
Stamm 20 BMMNC/20 C 
7-9 w 
 
90-250 ml, 
immune sel. 
133+/CD34+ 
6.0x106 
Graftable 
infract 
area 
ECHO EF↑, 
SPECT-viability↑ 
Zhao 
 
18 BMMNC/18 C 
 
18-21±17 
m 
 
30 ml, Ficoll, 
6.6x108 BMMNC 
Graftable 
infract 
area, 
EF<40% 
ECHO - EF↑, 
volumesŅ, 
regional function 
↑, SPECT↑ 
MAGIC 
30 HDMy/33 
LDMy/34 C 
>4 w 
 
10 g of tigh 
muscle, 3 w of 
culturing, HDMy-
800x106, LDMy-
400x106 
Graftable 
15%≥EF 
≤35% 
ECHO - EFņ, 
ESVŅ in HDMy 
group 
Endocardial      
Perin 
14 BMMNC/7 C 
 
>3 m 
 
50 ml, Ficoll, 
5.7±6.1x104CD34+ 
Ineligible 
for revasc. 
EF<40% 
LVA - EF↑, EMM 
- viability↑ 
Pokusha
lov 
 
55 BMMNC/54 C 
 
>12 m, 
9±8 y 
 
NS, Ficoll, 
1.0±0.6x106CD34+ 
 
Ineligible 
for 
revasc.EF<
45% 
ECHO - EF↑, 
SPECT - 
viability↑, 
functional 
status↑,  6 min 
WT↑ 
SEISMIC 
 
26 My/14 C 
 
8 y IQR 
4-12 
 
10 g of tigh 
muscle, 2-3 w of 
culturing, My-100-
400x106 
Ischemic 
HF 
RNV-MUGA - 
EFņ, functional 
status trend↑ 
 
Ramshor
st 
25 BMMNC/25 C NS 
80 ml, Ficoll, 
40x106MNC 
Ineligible 
for revasc. 
EF<40% 
SPECT↑, MRI - 
EF↑ 
 
I.C.- intracoronary, I.M. intramyocardial- during CABG, BMC-Bone marrow cells, BM-MNC – Bone 
marrow mononuclear cells, CPC-circulating progenitor cells, EPC- endothelial progenitor cells, My- 
Myoblasts, HD- high dose, LD- low dose, Bone marrow mesenchymal stem cells, PB-peripheral blood, 
C-controls, IQR- interquartile range,  CABG- coronary artery bypass grafting, revac.- revascularization, 
HF- heart failure, dECHO- dobutamine echocardiography, gSPECT- gated single-photon emission 
computed tomography, PET- positron emission tomography, MRI- magnetic resonance imaging, RNV- 
radionuclide ventriculography, 6 min WT- six minutes walking test, LVA- left ventricle angiography, 
EMM- electro-mechanical-mapping,  IVUS- intravascular ultrasound, MLA- minimal lumen area, EF- 
ejection fraction. 
 
 
Table 3. Important clinical trials of stem cell therapy for CMI. 
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Clinical trials of stem cell therapy in CMI (Table 3) are smaller and not so well conducted 
as trials of stem cell therapy in AMI (Sanz-Ruiz et al, 2010; Donndorf et al, 2011). 
According to coronary status we can divide patients with CMI in two groups, the first one 
eligible for revascularization of the infracted area and the second with no option of 
revascularization. We believe that it is very important to perform as complete as possible 
revascularization before the stem cell therapy and not to proceed to sophisticated stem 
cell trial in ischemic cardiomyopathy without knowing the coronary status of enrolled 
patients (C-CURE, NCT00810238). Again, the different modes of stem cells and methods 
of delivery might be necessary in those two groups. Based on some animal models 
(Hou et al, 2005) and on the logical assumption the direct intramyocardial (trans-
epicardial in patients who need surgical revascularization and trans-endocardial in 
patients who have no option of revascularization) route of stem cell delivery might be a 
preferred option.   
Transplantation of Progenitor Cells and Recovery of LV Function in Patients with Chronic 
Myocardial Infarction (TOPCARE-CHD) was the first randomized, cross-over study 
examining the role of intracoronary bone marrow stem cell therapy for CMI (Assmus et al, 
2006).  The transplantation of bone marrow derived MNC was associated with the modest 
but significant improvement of six-months LVEF (ΔLVEF=4.8% measured by MRI) and 
regional myocardial function. The improvement of the functional status assessed by the 
NYHA classification was also significant in the BMMNC group.  The second large, not 
randomized but well controlled study was Stem cell Transplantation in 191 patients with 
chronic heart failure - STAR-heart study (Strauer et al, 2010). 
The intracoronary injections of BMMNC had sustained (3 months – 5 years) beneficial effect 
on LV global and regional function, increased exercise capacity, improved functional 
capacity and reduced mortality compared to controls.  Myocardial Regeneration and 
Angiogenesis in Myocardial Infarction study (MAGIC-DES) compared the influence of 
intracoronary injections of G-CSF mobilized PBPC on LV performance between patients in 
AMI and CMI previously treated with drug-eluting stents (Kang et al, 2006). Only patients 
with AMI had improvement of LVEF after 6 months. The study of Ang, compared intra 
coronary (through the graft) and intramyocardial injection of bone marrow derived MNC 
and controls during CABG (Ang et al, 2006). Stress echocardiography did not reveal any 
improvement in viability in the akinetic segment. MRI follow-up was done in only one third 
of patients in this study.  
The first small study of application bone marrow derived MNC into the myocardium was 
the study of Hamano (Hamano et al, 2001). They injected bone marrow MNC into the non-
graftable area during the coronary artery bypass grafting (CABG) and found that the 
procedure was feasible, safe and that induced improvement of myocardial perfusion 
assessed by SPECT in 3/5 patients. The detailed description of patients was not presented.  
Patel conducted the first randomized trial with intramyocardial injections of enriched 
suspension of CD34+ cells during the off-pump CABG in patients with severe ischemic 
cardiomyopathy (Patel et al, 2005). Intramyocardial bone marrow derived MNC 
transplantation with off-pump CABG led to significant improvement of 6 months LVEF and 
functional status compared to patients treated with surgery only.   
In the randomized trial of Mocini injections of bone marrow MNC into the peri-infarcted 
and infracted region (only patients with recent infarction were included) after the CABG 
during the cardiac arrest was compared to CABG alone (Mocini et al, 2006). The patient 
cohorts had moderate LV systolic dysfunction (inclusion criteria was baseline EF>35%). 
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There was no increase of serious arrhythmias. Transplanted patients had significant 
improvement of EF and WMSI measured by MRI after 6 months compared to the controls. 
The relatively small randomized study of Hendrikx demonstrated only improvement of 
regional, but not the global systolic function by 6-months MRI follow-up with the bone 
marrow MNC myocardial injections after CABG (Hendikx et al, 2006). Interestingly the 
number of CD34+ cells injected was significantly higher in the responder group what 
implied the possible importance of cell dosing.  
The randomized study of Stamm, investigated the influence of more premature CD133+ cell 
myocardial injections after CABG on myocardial function and perfusion (Stamm et al, 2007).  
The significant improvement of EF and myocardial viability was detected after 6 months in 
the cell therapy group. Subgroup analysis showed that patients with the lower EF had the 
greater benefit for selected stem cell therapy. The injection of selected more premature cells 
was safe.  
The study of Zhao corroborated with the previous investigations, and verified the benefit of 
intramyocardial injections of MNC during CABG in patients with severe impaired EF post-
infarction on global and regional myocardial function and perfusion (Zhao et al, 2008).   
Very interesting non-randomized, case control study comes from Thailand’s group, who 
used thoracoscopic delivery of in-vitro expanded endothelial progenitors (EPC) isolated 
from the peripheral blood into the peri-infarction area (Arom et al, 2008). The subset of 
patients received combined EPC therapy with off-pump CABG. They enrolled patients with 
very severe ischemic heart disease and low basal EF (26±7%). EPC transplantation improved 
significantly LVEF even combined or not with CABG. This study is important because it gives 
a possible solution for very ill patients with chronic ischemic cardiomyopathy and with no 
option for revascularization. The procedure is minimally invasive, safe and might help. 
The clinical application of stem cell therapy had started with intra-myocardial injection of 
myoblasts. Menasche reported the first successful case on myoblast implantation during 
CABG and significant improvement of EF throughout 6 months (Menasche et al, 2001). 
Seven years later definitive results of Myoblast Autologous Grafting in Ischemic 
Cardiomyopathy (MAGIC) trial were published (Menasce et al, 2008).  The study had three 
arms, high and low-dose myoblast groups and a placebo group. Myoblasts were obtained 
from thigh biopsy and in vitro cultivation for three weeks. All patients received implantable 
cardioverter-defibrilator at the time of tight biopsy. Myoblasts were injected neighboring the 
akinetic segments. The modest increase of EF after 6 months was noticed in all groups 
equally. Nevertheless, patients who received high number of myoblasts had a significant 
decrease of end-systolic volume.   
Transmyocardial route of stem cell delivery guided with electro-mechanic mapping (NOGA 
system) represents an alternative option for the treatment of patients ineligible for 
conventional revascularization. Perin’s group conducted the pioneering, non-randomized 
but controlled study of trans-endocardial bone-narrow MNC injections using the 
electromechanical mapping (NOGA system) to guide cell injections into the viable but not 
mechanically functional myocardium (Perin et al, 2003). Patients treated with cell therapy 
had a greater increase of EF measured by RNA, reduction of reversible defect on SPECT and 
improved functional status after 2 and 4 months follow-up.   
Four relatively larger randomized studies with trans-endocardial application of bone 
marrow derived MNC or myoblasts have been recently published. Pokushalov’s group 
(Pokushalov et al, 2010) randomized patients with end-staged ischemic cardiomyopathy 
with chronic MI were assigned to trans-endocardial injections of bone marrow MNC and 
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the control group. Cell therapy provided the significant improvement in functional status, 
angina score, myocardial perfusion and global EF in comparison to control arm. Mortality 
also significantly decreased in cell therapy group (10.9% compared to 38.9%, p<0.001). 
The extremely valuable study comes from Ramshort group. They examined a role of 
trans-endocardial injections of bone marrow derived MNC into the electrically alive but 
functionally inactive myocardium in patients with severe, refractory angina and without 
additional option of revascularization (Ramshort et al, 2009). More than half number of 
patients had had previous MI in both cell therapy group and control group. Stress-
induced ischemia was reduced after 3 months and slight improvement of LVEF was 
demonstrated with cell therapy. This therapy also significantly improved the clinical 
status of patients.  
 Other two studies (SEISMIC and CAuSMIC) implanted cultured autologous myoblasts vie 
NOGA guiding system in patients with severe ischemic heart disease, previous infarction 
and chronic heart failure symptoms (Dib et al, 2009; Duckers et al, 2011). A high percentage 
of patients in both studies had previously ICD implanted. There was favorable safety with 
no difference between groups in arrhythmias and deaths. In both studies there was a 
functional improvement in myoblast groups, but SEISMIC study did not show any EF 
increase, and CAUSMIC sustained reduction of LV diameters.  
Two pilot trials with adipose derived stem cells (ADSC), one with intracoronary injections 
of ADSC in patients with STEMI (A Randomized Clinical Trial of Adipose-Derived Stem 
cells in the Treatment of Patients With ST-Elevation myocardial Infarction - The APOLLO 
Trial) and one with intra-myocardial injections of ADPC in patients with severe ischemic 
heart disease and illegible for revascularization (adipose-derived stem & Regenerative Cells 
In the Treatment of Patients With Non revascularizable ischemic Myocardium - The 
PRECISE Trial) showed feasibility, safety and initial promising results. 
4. Our experience 
Forty two patients enrolled in the REANIMA study (Regeneration of myocardium with 
bone marrow mononuclear cells in myocardial infarction) underwent the autologous, bone 
marrow derived stem cell therapy for myocardial infarction in our Institution (Military 
Medical Academy, Belgrade) in the period from February 2004 to September 2010. The Local 
Ethical Committee approved the study and the informed written consent was obtained from 
all participants. All patients reperfused successfully with primary percutaneous coronary 
intervention or by thrombolytic therapy (accelerated protocol with Actilyse, Boehringer-
Ingelheim) between 2-12 hours from the pain onset. 
Three groups were formed. Group I received intracoronary injection of bone marrow 
derived MNC on 6-12 day after MI; group II received intracoronary injection of bone 
marrow derived MNC in the chronic phase of infarction; and group III received bone 
marrow derived MNC intramyocardially during the CABG. The inclusion criteria for the 
first group were the presence of the first MI, age under 70 years, opened infarct related 
artery on the 5th day of infarction, LVEF≤40% on the 5th day, and the clinically stable patient.  
The inclusion criteria for the II group were age under 70, MI at least 2 months before stem 
cell therapy, clinically stable patient, and LVEF≤40%. Finally, the inclusion criteria for the III 
group were age under 70, indication for CABG, the graftable infarction related area, 
LVEF≤45%, and the clinically stable patient. The common exclusion criteria were the 
presence of the important comorbidities (systemic or cardiac).  
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In AMI group baseline echocardiography assessment was performed between 4-7 days. The 
LVEF was determined according to the Simpson’s rule, wall motion score index at rest and 
end-diastolic and end-systolic volume indices were measured. Examination was repeated in 
the sixth month after MI.  
Single-photon emission tomography (SPECT) with Technetium 99m-sestamibi was done 
between 4-7 day and in the 6th month. The infarction size (IS) of left ventricle (LV) was 
quantified by the commercial software (AutoQuant software, Cedars-Sinai QPS/QGS 
component of AutoQuant) as an area of LV (in percentage) with the uptake of tracer less 
than 50% of the maximal value.  
Twenty-four hour ECG Holter was done in all patients in the second month from cell therapy.  
The harvest of bone marrow was done in the morning of cell therapy. For intracoronary 
MNC delivery, between 250-350 ml of bone marrow was harvested under the general 
anesthesia with the multiple aspirations from the posterior iliac crests. After harvesting, cell 
suspension was filtered twice and processed with the COBE SPECTRA to reduce the 
number of red cells and platelets. The total final cell suspension volume was 150 ml, and the 
total cell number was between 10-50x109/μl. MNC represented 25-40% of these cells, and 
CD34+ cells were between 1.5-2.0% of it. Cell suspension was given through the diagnostic 
catheter deeply positioned in the LM. Boluses of 20 ml were given during 1 minute with 2 
minutes pauses apart from the injections. Transient ST segment elevation was noticed in 
every patient. A slight increase of troponin was detected in one patient in CMI and one in 
AMI group after the procedure with minimally prolonged chest pain.  
The bone marrow harvest (150 ml) for intramyocardial cell transfer was done under the 
general anesthesia immediately before the CABG. Cells were processed manually and after 
several filtration and centrifugation steps total volume of 15-20 ml was prepared. 
Preparation of cells was done during the operation, and cell injections of 20-30x0.3 ml per 
injection were performed after the end of operation during the cardiac arrest in the 
myocardial area adjacent to necrotic core.  The mean number of intramyocardial injected 
CD34+ cells was 2.2±1.1x106 cells. Time from the bone marrow harvest to MNC application 
was 3-4 hours in all three groups.   
 
Charcteristics 
Intracoronary 
BMMNC in 
AMI (N=19) 
Intracoronary 
BMMNC in CMI 
(N=9) 
Intramyocard.BM
MNC CMI-CABG 
(N=14) 
P 
Age - y±SD 50±11 50±12 54±11 NS 
Gender - n (%)     
Female 3 (15.8) 2 (22.2) 0 (0.0) NS 
Risk factors     
Diabetes – n (%) 2 (10.5) 1 (11.1) 3 (21.4) NS 
Hypertension – n (%) 8 (42.1) 3 (33.3) 7 (50.0) NS 
Active smoking – n (%) 13 (68.4) 5 (55.6) 5 (35.7) NS 
Hypercholesterolemia – n (%) 12 (63.2) 5 (55.6) 8 (57.1) NS 
Infarct related artery – n (%)     
LAD 18 (94.7) 9 (100.0) 11 (78.6) NS 
LCX 1 (5.3) - 1 (7.1)  
RCA - - 2 (14.3)  
Table 4. Baseline demographic data of study patients. BMMNC- bone marrow mononuclear 
cells, AMI- acute myocardial infarction, CMI- chronic myocardial infarction, CABG- 
coronary artery bypass grafting,  LAD- left anterior descending, Left circumflex artery, 
RCA- right coronary artery. 
www.intechopen.com
Stem Cell Therapy in Myocardial InfarctionClinical Point of View and the Results of the 
REANIMA Study (REgenerAtion of Myocardium with boNe Marrow Mononuclear Cells in… 
 
247 
Baseline demographic characteristics of patients (Table 4) were similar throughout groups. 
Patients with CMI treated with intracoronary injections of bone marrow MNC had lower 
LVEF, larger end-diastolic and end-systolic volumes indices and larger infarction size at 
baseline and after 6 months.  
Left ventricle EF significantly increased in patients with intracoronary injections of bone 
marrow MNC after AMI (ΔLVEF=5.5±6.6%) and in patients treated with intramyocardial 
injections of bone marrow MNC (ΔLVEF=5.0± 4.2) and there was no change of LVEF in 
patients with intracoronary injections of bone marrow MNC in CMI (Figure 2). The 
infarction size was significantly reduced in patients with intracoronary injections of bone 
marrow MNC after AMI (ΔIS=6.2±5.0%) and in patients treated with intramyocardial 
injections of bone marrow MNC (ΔIS=4.9± 4.3) and there was no change of infarction size in 
patients with intracoronary injections of bone marrow MNC in CMI (Figure 2).  
 
End-points 
Intracoronary 
BMMNC in AMI
N=19 
Intracoronary 
BMMNCin CMI
N=9 
Intramyocardial 
BMMNC in CMI 
after CABG N=14 
P value 
between  3 
groups 
Baseline LVEF (%) 33.1±4.1 30.8±4.4 35.3±3.9 0.05 
6-m LVEF (%) 38.6±8.3 29.9±6.53 40.3±5.4 0.01 
ΔLVEF % 5.5±6.6 -0.9±2.7 5.0±4.2 0.01 
 P =0.002 P=0.354 P=0.001  
Baseline EDVCI ml/m2 68.2±11.3 90.8±29.3 70.3±22.5 0.02 
6-m EDVCI ml/m2 72.5±12.8 94.2±35.1 70.7±15.3 0.02 
ΔEDVCI ml/m2 -4.4±10.1 -3.5±12.4 -0.4±13.2 0.63 
 P=0.080 P=0.428 P=0.920  
Baseline ESVCI ml/m2 44.1±9.9 63.4±23.7 48.4±15.3 0.01 
6-m ESVCI ml/m2 44.5±11.0 65.3±30.3 42.1±10.9 0.01 
ΔESVCI ml/m2 -0.3±7.8 -1.9±9.6 6.3±11.0 0.07 
 P=0.852 P=0.575 P=0.050  
Baseline IS (%) 30.3±8.5 37.9±9.1 28.9±4.1 0.19 
6-m IS (%) 25.3±11.0 37.4±8.4 22.7±5.2 0.01 
ΔIS 4.9±4.3 0.4±1.4 6.2±5.0 0.02 
 P<0.001 P=0.377 P<0.001  
Table 5. Left ventricle ejection fraction (LVEF) and infarction size (IS) at baseline and after 6 
months. 
Although improved LVEF, intracoronary bone marrow MNC transfer in patients with AMI 
did not block remodeling of the left ventricle. There was a trend toward significant increase 
of LV end-diastolic volume index in those patients (Table 5). On the other side, patients 
treated with intramyocardial bone marrow MNC injections with CABG had a positive effect 
on end-systolic volume index which significantly decreased after 6 months. In patients with 
CMI, there were no significant changes of either LVEF, or volume indices, or IS after six 
months (Table 5). 
After six months of follow up, there were no deaths in any group (Table 6). Other important 
clinical event is showed in the table 6. We did not observe any significant arrhythmias on 24 
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hours ECG Holter during the follow-up of six months. Patients with CABG and cell therapy 
were the most stable. Also, functional NYHA class in six months was lower in CABG plus 
cell therapy treated patients compared to other two groups.  
 
 
  
Fig. 2. Changes of LVEF and IS between 6-months and baseline measurements across the 
three groups. I.C. BMMNC-CMI- Intracoronary bone marrow mononuclear cells in chronic 
myocardial infarction; I.M.BMMNC-CABG- intramyocardial bone marrow mononuclear 
cells in chronic myocardial infarction after coronary artery bypass grafting; I.C.BMMNC 
AIM- intracoronary bone marrow mononuclear cells in acute myocardial infarction 
 
Major adverse cardiac 
events 
Intracoronary 
BMMNC in AMI 
(N=19) 
Intracoronary 
BMMNC in CMI 
(N=19) 
Intramyocardial 
BMMNC in CMI 
after CABG (N=14) 
Revascularization n (%) 4 (21.1) 1 (11.1) - 
Heart failure – n (%) 3 (15.8) 4 (44.4) 1 (7.1) 
NYHA class 6 months 1.58 1.14 1.89 
Table 6. Major cardiac adverse events after 6 month follow-up.BMMNC- bone marrow 
mononuclear cells, AMI - acute myocardial infarction, CMI - chronic myocardial infarction, 
CABG - coronary artery bypass grafting 
Our study is small and non-randomized, but nevertheless, suggests two important 
conclusions. The first is that bone marrow derived, native stem cells showed the 
improvement of the left ventricle function and a decrease of infarction size in both patients 
with AMI and CMI, and the second, direct intramyocardial delivery of bone marrow 
derived MNC is probably more efficient than intracoronary route of administration in 
patients with CMI. In our previous study (Obradovic et al, 2009a, 2009b) we compared 
function of LV and reduction of infarction size in patients with acute myocardial infarction 
treated with intracoronary bone marrow cell injections to well-matched control group and 
showed trend of improvement of LVEF and significant reduction in infarction size in cell 
therapy group. The improvement of LVEF by 5% in our trial of AMI patients is in 
accordance with the results of REPAIR AMI trial (Schachinger et al, 2006a, 2006b) and the 
result of meta-analysis of intracoronary bone marrow derived stem cell transplantation in 
AMI patients (Abdel-Latif et al, 2007).  
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The outcome of stem cell therapy depends on different factors. The proper selection of 
patients, timing and methodology of stem cell therapy is crucial for improvement. In AMI 
we have a reasonable assumption that patients with lower LVEF had increased benefit of 
bone marrow derived stem cell therapy. However, among larger trials with intracoronary 
bone marrow derived stem cell therapy for AMI, only REGENT trial (Tendera et al, 2009) 
have had the entrance criteria of LVEF<40%, but it has not been stated when and how LVEF 
was measured, because it is not equal if it is measured on admission, or 2-3 days after the 
reperfusion therapy, and it is difficult to explain how the median of LVEF in this study was 
37% with the such entrance criteria for LVEF. This implies some recruitment bias. The 
entrance echocardiogram in our study was performed on the 4-5 days after AMI to avoid 
myocardial stunning which is very pronounced in the first few days of AMI, and we suggest 
that entrance LV performance should be measured on the 3rd-4th day after AMI and not on 
admission or within the first 48 hours.  
But is there a lower border of infarction damage when the stem cell therapy has no 
benefit? In our study (Obradovic et al, 2009) we showed that patients with too large 
myocardial infarction (measured by the perfusion defect on SPECT and by the maximum 
serum lactate dehydrogenase activity during the acute phase of STEMI) have no benefit of 
single, intracoronary stem cell therapy. Those patients might need repeated stem cell 
injections like in Chinese study (Yao et al, 2009) with the repeated intracoronary bone 
marrow cell transplantation three months after the AMI with the similar cohort of patients 
as ours.   
It seems that intracoronary bone marrow stem cell therapy in early days of stem cell therapy 
also has no effect (Zhang et al, 2009), because the stem cells are injected in a very hostile, 
inflammatory, ischemic environment full of toxins. But, there are no randomized trials 
comparing stem cell therapy, for instance between 1-5 days to 6-12 days after infarction. 
Like in the most studies with intracoronary transplantation of stem cells in AMI, we injected 
cells intracoronary in the second week of infarction, not too soon from the initial event and 
not too late from it, to be in the burst of reparation process.   
However, MYSTAR trial (Gyöngyösi et al, 2009) demonstrated that stem cell therapy after 3 
weeks and 3 months had resulted in similar benefit on LV function. Having in mind that 
finding, our experience and previous reports we can only conclude that we do not know the 
proper timing for stem cell therapy after AMI.  
What kind of cells we need in AMI, and do we need another cell type or types for CMI? In 
our study we only use the filtration of bone marrow and concentration of their mononuclear 
cells. We suppose that different kind of cells and their interplay is important for the 
successful cell therapy in AMI. The immune selection of bone marrow stem cells without 
some in-vitro manipulation of cells is probably unnecessary, especially in AMI patients. 
What do we gain and what do we lose with this procedure? The same number of cells with 
certain phenotype would be given with, or without selection, and a selection procedure 
would for sure prolong the timing from the bone marrow harvest to its application and 
further damage. The preparation of cells is important, however, at least for patients with 
AMI it is more important to give appropriate number of viable and functioning cells and the 
duration of bone marrow processing should be short. In the REGENT trial, immune-
selection of CD-34+/CXC4R+ cells did not bring any advantage compared to un-selected 
bone marrow mononuclear cells.  
Again there is no clinical randomized trial comparing different methods of stem cell 
processing. Do we need mesenchymal stem cells for AMI or CMI patients? Very well 
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conducted study (Chen et al, 2004), with successful intracoronary implantation of 
mesenchymal stem cells in patients with AMI is almost neglected and those results are not 
challenged.  
The way of cell delivery is also a matter of controversy. For intracoronary delivery almost all 
studies have used the same method (Strauer et al, 2002) nevertheless, the animal model 
suggests that the injections of cells through the inflated balloon currently applied in clinical 
studies are not necessary for cell deposit (Tossios P, et al, 2008). So, our study also has 
showed that non-selective injections of bone marrow MNC into the left coronary artery 
proved to be efficient in improving the LVEF and diminishing the infarction size. There is 
no human trial addresses for that issue. There are also numerous tips and tricks for stem cell 
delivery that might be important. Strauer used albumin-microaggregates to ensure 
prolonged passage of stem cells through the infracted microcirculation, and dobutamine 
infusion (Strauer et al, 2010) to increase the demand of oxygen in myocardium and probably 
to enhance engratment of stem cells with such treatment. However, does the freshly 
infracted myocardium need such an ischemic push? We have noticed very clear ischemic 
changes on electrocardiography monitoring in every patient during the delivery of cell 
suspension.  
Intracoronary way of cell delivery is probably more suitable for the AMI patients because it 
enables homogenous spread of stem cells throughout the infracted microcirculation full of 
chemoattractants. On the other hand, a direct intramyocardial injection of stem cells in patients 
with CMI seems to be preferred mode of cell delivery. Some animal model and pilot human 
trial confirm this assumption (Hou et al, 2005; Schächinger et al, 2008). Our results have shown 
benefit of bone marrow derived stem cells given into the myocardium during CABG  
improving LVEF and myocardial perfusion which is in accordance with other studies of bone 
marrow derived stem cell therapy with CABG (Donndorf et al, 2011). On the other hand, our 
results have not shown any benefit of intracoronary transplantation of bone marrow stem cells 
in patients with CMI. There are only 2 published studies with intracoronary transplantation of 
bone marrow derived mononuclear cells in CMI and the both of them demonstrated 
improvement of LV performance after the procedure (Assmus et al, 2006; Strauer et al, 2009). 
The way of trans-balloon application of stem cells was used in both studies and on the 
contrary we used non-selective intracoronary implantation of stem cells. This distinction might 
have the different outcome between our and the mentioned studies and underlines the 
importance of ischemic preconditioning in this cohort of patients.  
Finaly, and probably the most important aspect of stem cell therapy is a clinical benefit. 
REPEAR-AMI (Schächinger et al, 2010), studies of Strauer’s group in AMI (Yousef et al, 2009) 
and CMI (Strauer et al, 2010) and the largest study with endocardial implantation of bone 
marrow derived stem cells in CMI (Pokushalov et al, 2010) have showed clear clinical benefit 
with hard end points during the relatively long period of follow-up. In our study, we have not 
a sufficient number of patients to show the difference of major adverse cardiac events in 
several groups of our patients. Nevertheless, there were no deaths during the 6 months follow-
up, and the number of patients with restenosis and symptomatic heart failure was low.  
When we take into account the benefit of stem cell therapy in the treatment of myocardial 
infarction one scenario is possible. Stem cells do not improve significantly global or even 
regional myocardial infarction after MI but do stabilize myocardium on the molecular level 
with the long-term clinically important benefits through yet unknown mechanisms.  
As you can easily realize, there are too many confounding, important factors. It is 
impossible to randomize all the possibilities. Logic is important but it does not mean that it 
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is always right. Clinical trials in stem cell therapy are being done too fast, and many trials 
did not meet the entrance criteria of sample size for the right statistical power. The 
European Task Force for stem cell therapy in cardiovascular diseases does not recommend 
the stem cell therapy in wider clinical practice and recommends large, placebo controlled 
trials (Bartunek et al, 2006). However, do we know enough to create the proper, large 
clinical trial for stem cell therapy? We believe that centrally coordinated, well-organized, 
small, always multicentric, pilot trials that address the various issues of stem cell therapy 
must precede the creation of a large randomized trial. 
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